Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: 613 who wrote (57760)	7/5/2000 11:20:10 AM
From: steve h	Read Replies (1) \| Respond to of 122087

613, I'm not afraid of a long list of contrainidcations. I am concerned that arrhythmia and coumadin patients significantly cut into the treateable population. So we also need to remember, a large population of patients that suffer from a disease do not necessarily become EECP patients. Again, I do not know, what percentage of angina patients are treatable via EECP. Nor do I know how many physicians would recommend this type of treatment. Could you provide stastisitcs on the number of angina patients that are not on coumadin already or don't have a preexisting arrhythmia condition? Please provide a literature reference if possible. You do make a very good point though, If they are bought out by a larger company, their therapy/equipment can be combined with other forms of cardiac therapy as part of a larger more comprehensive cardiovascular package. This adjunct marketing strategy could be very powerful. A significant increase in company value is not totally dependent on a buy-out. Another optionn would be a distribution agreement with a large medical company that would significantly increase their network. Steve h